CDX2 and digestive system carcinoma: While comparing the usefulness of CDH17 in immunohistochemical diagnostics in gastrointestinal carcinomas with CDX2, it has been observed that almost all colon adenocarcinomas (99%) are CDH17-positive/CDX2-positive [243].